Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer

Taylor, Sarah

367
Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

S. E. Taylor¹, R. Li², J. S. Petschauer³, H. D. Donovan², W. C. Zamboni³, R. P. Edwards¹ and K. K. Zorn⁴
¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of Arkansas for Medical Sciences, Little Rock, AR

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

367
Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer

367 Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer

367
Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer